CORRECTION: AstraZeneca Q2 Adj. EPS $1.98 Inline, Adj. EPADS $0.99, Sales $12.98B Beat $12.60B Estimate
Portfolio Pulse from Benzinga Newsdesk
AstraZeneca (NASDAQ:AZN) reported Q2 adjusted EPS of $0.99, missing the analyst consensus estimate of $1.20 by 17.5%. This represents a 7.91% decrease from the same period last year. However, the company reported quarterly sales of $12.98 billion, beating the analyst consensus estimate of $12.75 billion by 1.83% and marking a 13.73% increase from the same period last year.
July 25, 2024 | 1:17 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
AstraZeneca's Q2 adjusted EPS of $0.99 missed analyst estimates by 17.5%, representing a 7.91% decrease YoY. However, quarterly sales of $12.98 billion beat estimates and increased by 13.73% YoY.
The significant miss on EPS is likely to negatively impact the stock price in the short term, despite the positive sales performance. Investors often react more strongly to earnings misses than sales beats.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100